10x Genomics (TXG) Total Non-Current Liabilities (2018 - 2026)

10x Genomics (TXG) has 9 years of Total Non-Current Liabilities data on file, last reported at $195.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 2.05% year-over-year to $195.0 million; the trailing twelve-month figure through Mar 2026 stood at $195.0 million (up 2.05% YoY), and the FY2025 full-year result was $238.6 million, up 14.42% from the prior year.
• Total Non-Current Liabilities eased to $195.0 million in Q1 2026, from $238.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $238.6 million in Q4 2025 to a low of $188.0 million in Q1 2022.
• A 5-year average of $207.0 million and a median of $204.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities climbed 18.01% in 2022 and decreased 10.02% in 2023, its largest moves.
• Tracing TXG's Total Non-Current Liabilities over 5 years: stood at $220.3 million in 2022, then decreased by 0.2% to $219.8 million in 2023, then fell by 5.15% to $208.5 million in 2024, then advanced by 14.42% to $238.6 million in 2025, then retreated by 18.26% to $195.0 million in 2026.
• Business Quant data shows TXG's Total Non-Current Liabilities at $195.0 million in Q1 2026, $238.6 million in Q4 2025, and $235.8 million in Q3 2025.